Macrolides vs. quinolones for community-acquired pneumonia: Meta-analysis of randomized controlled trials

Clinical Microbiology and Infection

Volumn 19, Issue 4, 2013, Pages 370-378

  Skalsky, K ^a   Yahav, D ^a,b   Lador, A ^a   Eliakim Raz, N ^a   Leibovici, L ^a,b   Paul, M ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Fluoroquinolones; Macrolides; Meta analysis; Pneumonia; Systematic review

Indexed keywords

AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CLARITHROMYCIN; CLAVULONE DERIVATIVE; ERYTHROMYCIN; GARENOXACIN; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; SPARFLOXACIN; TROVAFLOXACIN;

ARTICLE; CHLAMYDOPHILA PNEUMONIAE; COMMUNITY ACQUIRED PNEUMONIA; CONFIDENCE INTERVAL; DIARRHEA; DISEASE SEVERITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; LEGIONELLA; MYCOPLASMA PNEUMONIAE; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

EID: 84875513038     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03838.x     Document Type: Article

References (55)

1. Lim WS, Baudouin SV, George RC et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 (suppl 3): iii1-iii55.
2. Mandell LA, Marrie TJ, Grossman RF et al. Summary of Canadian Guidelines for the Initial Management of Community-acquired Pneumonia: An evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can J Infect Dis 2000; 11: 237-248.
3. Niederman MS, Mandell LA, Anzueto A et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-1754.
4. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis, 2007; 44 (suppl 2): S27-S72.
5. Martin-Loeches I, Lisboa T, Rodriguez A et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010; 36: 612-620.
6. Griffin AT, Peyrani P, Wiemken T et al. Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study. Int J Tuberc Lung Dis 2010; 14: 495-499.
7. Ye X, Sikirica V, Schein JR et al. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis. Clin Ther 2008; 30: 358-371.
8. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2008. Available from http://www.cochrane-handbook.org (last accessed 20 September 2010).
9. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://www.cochrane-handbook.org (last accessed 29 March 2012).
10. Higgins JP, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
11. Review Manager (RevMan). 5.1 ed. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration 2011.
12. D'Ignazio J, Camere MA, Lewis DE et al. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults. Antimicrob Agents Chemother 2005; 49: 4035-4041.
13. Fogarty C, Grossman C, Williams J et al. Efficacy and safety of moxifloxacin vs clarithromycin for community- acquired pneumonia. Infections in Medicine 1999; 16: 748-763.
14. Gotfried MH, Dattani D, Riffer E et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clin Ther 2002; 24: 736-751.
15. Hoeffken G, Meyer HP, Winter J et al. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med 2001; 95: 553-564.
16. Lode H, Aronkyto T, Chuchalin AG et al. A randomised, double-blind, double-dummy comparative study of gatifloxacin with clarithromycin in the treatment of community-acquired pneumonia. Clin Microbiol Infect 2004; 10: 403-408.
17. Nielsen PB, Husfeldt P, Egede F. Ofloxacin vs erythromycin in community-acquired pneumonia in general practice. Drugs 1993; 46: 421-422.
18. Ramirez J, Unowsky J, Talbot GH et al. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. Clin Ther 1999; 21: 103-117.
19. Sokol WN Jr, Sullivan JG, Acampora MD et al. A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia. Clin Ther 2002; 24: 605-615.
20. Lode H, Garau J, Grassi C et al. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin. Eur Respir J 1995; 8: 1999-2007.
21. Nguyen TH, Fiel T, Seas C, et al. Oral Garenoxacin (GRN) 400mg QD vs Clarithromycin (CLR) 500mg BID in the Treatment of Community-Acquired Pneumonia (CAP). In: Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C.: American Society for Microbiology. December 16-19, 2005 abstract no.
22. Ramirez J, Nguyen T-H, Tellier G, et al. Once daily 400mg oral gatifloxacin vs. twice daily 500mg oral clarithromycin in the treatment of community aquired pneumonia. Interscience Conference on Antimicrobial Agents and Chemotherapy. California 1999b:703.
23. Tellier G, Sullivan J, Fogarty C, et al.Double-Blind, Randomized 5-Day Garenoxacin (GRN) vs 7- to 10-Day Clarithromycin (CLR) to Treat Community-Acquired Pneumonia (CAP). In: Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C.: American Society for Microbiology. December 16-19, 2005: abstract no. L-567.
24. Alcacer F, Belda A, Custardoy J et al. Comparative study of ofloxacin versus erythromycin in the treatment of community-acquired pneumonia. Rev Esp Quimioter 1993; 6: 213-218.
25. Gaillat J, Bru JP, Sedallian A. Penicillin G/ofloxacin versus erythromycin/amoxicillin-clavulanate in the treatment of severe community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1994; 13: 639-644.
26. Moola S, Hagberg L, Churchyard GA et al. A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia. Chest 1999; 116: 974-983.
27. Ortqvist A, Valtonen M, Cars O et al. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group. Chest 1996; 110: 1499-1506.
28. Richter SS, Heilmann KP, Dohrn CL et al. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin Infect Dis 2009; 48: e23-e33.
29. Drago L, Nicola L, Rodighiero V et al. Comparative evaluation of synergy of combinations of beta-lactams with fluoroquinolones or a macrolide in Streptococcus pneumoniae. J Antimicrob Chemother 2011; 66: 845-849.
30. Flippin HF, Lockwood JS, Pepper DS et al. The treatment of pneumococcic pneumonia with sulfapyridine: a progress report on observations in 100 cases. JAMA 1939; 112: 529-534.
31. Petersdorf RG, Cluff LG, Hoeprich PD et al. Pneumococcal pneumonia treated with penicillin and aspirin. Bull Johns Hopkins Hospital 1967; 101: 1-12.
32. Spellberg B, Talbot GH, Brass EP et al. Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia. Clin Infect Dis 2008; 47 (suppl 3): S249-S265.
33. Malhotra-Kumar S, Lammens C, Coenen S et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 2007; 369: 482-490.
34. Berg HF, Tjhie JH, Scheffer GJ et al. Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow-release clarithromycin: a randomized, double-blind, placebo-controlled study. Antimicrob Agents Chemother 2004; 48: 4183-4188.
35. Eisenblatter M, Klaus C, Pletz MW et al. Influence of azithromycin and clarithromycin on macrolide susceptibility of viridans streptococci from the oral cavity of healthy volunteers. Eur J Clin Microbiol Infect Dis 2008; 27: 1087-1092.
36. Matute AJ, Schurink CA, Krijnen RM et al. Double-blind, placebo-controlled study comparing the effect of azithromycin with clarithromycin on oropharyngeal and bowel microflora in volunteers. Eur J Clin Microbiol Infect Dis 2002; 21: 427-431.
37. Beyer G, Hiemer-Bau M, Ziege S et al. Impact of moxifloxacin versus clarithromycin on normal oropharyngeal microflora. Eur J Clin Microbiol Infect Dis 2000; 19: 548-550.
38. Fantin B, Duval X, Massias L et al. Ciprofloxacin dosage and emergence of resistance in human commensal bacteria. J Infect Dis 2009; 200: 390-398.
39. Barker PJ, Sheehan R, Teillol-Foo M et al. Impact of gemifloxacin on the normal human intestinal microflora. J Chemother 2001; 13: 47-51.
40. Edlund C, Nord CE. Ecological effect of gatifloxacin on the normal human intestinal microflora. J Chemother 1999; 11: 50-53.
41. van Nispen CH, Hoepelman AI, Rozenberg-Arska M et al. A double-blind, placebo-controlled, parallel group study of oral trovafloxacin on bowel microflora in healthy male volunteers. Am J Surg 1998; 176: 27S-31S.
42. Hsu LY, Tan TY, Tam VH et al. Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals. Antimicrob Agents Chemother 2010; 54: 1173-1178.
43. Lee YJ, Liu HY, Lin YC et al. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use. Int J Antimicrob Agents 2010; 35: 261-264.
44. Leibovici L, Berger R, Gruenewald T et al. Departmental consumption of antibiotic drugs and subsequent resistance: a quantitative link. J Antimicrob Chemother 2001; 48: 535-540.
45. Ray GT, Baxter R, De Lorenze GN. Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-nonsusceptible Pseudomonas aeruginosa. Clin Infect Dis 2005; 41: 441-449.
46. Tacconelli E, De Angelis G, Cataldo MA et al. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysisJ Antimicrob Chemother 2008; 61: 26-38.
47. Mahamat A, MacKenzie FM, Brooker K et al. Impact of infection control interventions and antibiotic use on hospital MRSA: a multivariate interrupted time-series analysis. Int J Antimicrob Agents 2007; 30: 169-176.
48. Bergman M, Huikko S, Huovinen P et al. Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2006; 50: 3646-3650.
49. Garcia-Rey C, Aguilar L, Baquero F et al. Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae. J Clin Microbiol 2002; 40: 159-164.
50. Granizo JJ, Aguilar L, Casal J et al. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979-1997). J Antimicrob Chemother 2000; 46: 767-773.
51. Riedel S, Beekmann SE, Heilmann KP et al. Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 2007; 26: 485-490.
52. Gottesman BS, Carmeli Y, Shitrit P et al. Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting. Clin Infect Dis 2009; 49: 869-875.
53. Schneider-Lindner V, Delaney JA, Dial S et al. Antimicrobial drugs and community-acquired methicillin-resistant Staphylococcus aureus, United Kingdom. Emerg Infect Dis 2007; 13: 994-1000.
54. Psaty BM. Clinical trial design and selected drug safety issues for antibiotics used to treat community-acquired pneumonia. Clin Infect Dis 2008; 47 (suppl 3): S176-S179.
55. Piaggio G, Elbourne DR, Altman DG et al. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006; 295: 1152-1160.